2005
DOI: 10.1212/01.wnl.0000191566.86977.04
|View full text |Cite
|
Sign up to set email alerts
|

α7-Acetylcholine receptor antibodies in two patients with Rasmussen encephalitis

Abstract: Rasmussen encephalitis (RE) sera were screened for antibodies to human alpha7 nicotinic acetylcholine receptors (nAChRs) using electrophysiology, calcium imaging, and ligand binding assays. Sera from two of nine patients with RE blocked ACh-induced currents through alpha7 nAChRs and the ACh-induced rise in intracellular free calcium ([Ca2+]i) and inhibited (125)I-alpha-bungarotoxin binding in cells expressing alpha7 nAChRs. Thus, the alpha7 nAChR is a potential target for pathogenic antibodies in patients with… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
35
0
2

Year Published

2007
2007
2024
2024

Publication Types

Select...
6
3
1

Relationship

1
9

Authors

Journals

citations
Cited by 69 publications
(38 citation statements)
references
References 11 publications
1
35
0
2
Order By: Relevance
“…Such antibodies act against neuronal acetylcholine receptors in the autonomic ganglia and are frequently found in patients with autoimmune autonomic ganglionopathy. Additionally, two rare cases of Rasmussen encephalitis with α7 AChR antibodies have been reported (46). It has also been reported that a low titer of gAChR antibodies is detected in the serum in a small number of patients with POTS (32).…”
Section: Etiologymentioning
confidence: 97%
“…Such antibodies act against neuronal acetylcholine receptors in the autonomic ganglia and are frequently found in patients with autoimmune autonomic ganglionopathy. Additionally, two rare cases of Rasmussen encephalitis with α7 AChR antibodies have been reported (46). It has also been reported that a low titer of gAChR antibodies is detected in the serum in a small number of patients with POTS (32).…”
Section: Etiologymentioning
confidence: 97%
“…However, further studies failed to support these findings; anti-GluR3 antibodies were infrequently found in RE or intractable epilepsies (Wiendl et al 2001;Watson et al 2004) and few patients showed sustained clinical improvement following plasmapheresis (Andrews et al 1996;Granata et al 2003). Additionally, antibodies against a number of other autoantigens, such as the a7-nicotinic receptor or Munc-18-1, have been reported in sera of a few RE patients (Watson et al 2005;Alvarez-Baron et al 2008), and the relevance of these antibodies is questionable. However, the presence of autoantibodies suggests that there is activation of the adaptive immune system and may be a secondary phenomenon following the intervention of cytotoxic T lymphocytes into the brain.…”
Section: Rementioning
confidence: 99%
“…13 However, these antibodies have not been consistently demonstrated in all patients with RE, 14 and their presence could also be demonstrated in other forms of severe epilepsy, 15 suggesting that they may reflect responses to injured CNS tissue. Subsequently, serum IgG autoantibodies against a7 nicotinic acetylcholine receptors (a7nAChR) were reported in a subset of patients with RE and described as specifically blocking the function of the neuronal a7nAChR, 16 an inflammatory regulator thought to play a role in blood-brain barrier regulation, which is likely to be damaged in RE. 17,18 In 2 independent studies, serum antibodies against the presynaptic SM (Sec1/Munc18-like) protein Munc-18 were found in a subset of patients with RE during early disease stages, with description of altered neurotransmitter release.…”
mentioning
confidence: 99%